2016 Half-Year Results

HY 2013 HY 2014 CORE EBITDA (CHF million) CORE definition: see appendix Corporate Significant Improvement in Both Segments Pharma&Biotech Specialty Ingredients CHF mn HY 2016 HY 2015 % YoY Sales 838 754 11.1 CHF mn Sales HY 2016 HY 2015 % YoY 1,165 1,131 3.0 CORE EBITDA 226 182 24.2 CORE EBITDA 241 217 11.1 Margin 27.0% 24.1% Margin 20.7% 19.2% CORE EBIT 159 117 35.9 CORE EBIT 194 172 12.8 Margin 19.0% 15.5% Margin 16.7% 15.2% HY 2015 300 30% 300 30% 27.0% 24.8 % 23.8 % 24.1% 241 25% 25% 217 201 195 200 226 20% 200 20% 20.7% 182 167 19.2% 15% 18.2% 17.2% 15% 100 145 10% 100 10% 5% 5% 0 0% 0 0% HY 2016 CORE EBITDA margin (%) HY 2013 HY 2014 CORE EBITDA (CHF million) HY 2015 HY 2016 CORE EBITDA margin (%) 6 Jul-16 Lonza

View entire presentation